0021-972X/04/$15.00/0 Printed in U.S.A.

The Journal of Clinical Endocrinology & Metabolism 89(7):3462–3468 Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032067

Breast and Uterine Effects of Soy Isoflavones and Conjugated Equine Estrogens in Postmenopausal Female Monkeys CHARLES E. WOOD, THOMAS C. REGISTER, MARY S. ANTHONY, NANCY D. KOCK, J. MARK CLINE

AND

Comparative Medicine Clinical Research Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157-1040 In this study we evaluated the long-term effects of soy isoflavones on intermediate markers of cancer risk in the normal postmenopausal monkey breast and uterus. Ovariectomized female cynomolgus monkeys were randomized to receive one of three diets for 36 months: 1) isoflavone-depleted soy protein isolate (SPIⴚ) (n ⴝ 57); 2) soy protein isolate with the equivalent of 129 mg/d isoflavones (SPIⴙ) (n ⴝ 60); or 3) isoflavonedepleted soy protein isolate with conjugated equine estrogens at a dose scaled to approximate 0.625 mg/d in women (n ⴝ 62). End points included breast and uterine proliferation markers, sex steroid receptor expression, and serum estrogens. Epithelial proliferation and progesterone receptor expression in the breast and uterus were significantly higher in the conjugated

S

OY ISOFLAVONES ARE phytoestrogenic compounds widely marketed and used as a natural alternative to traditional hormone therapy in postmenopausal women (1). Dietary supplementation with soy isoflavones is particularly common in women at high risk for breast cancer (1, 2) despite controversial evidence on the role of isoflavones in cancer risk. Epidemiologic studies have shown lower rates of breast and endometrial cancer among women consuming higher amounts of soy (3–9). Soy isoflavones have also been shown to protect against carcinogen-induced mammary tumors in rodents (10, 11) and induce a variety of antiproliferative and proapoptotic responses in cell culture (12–17). In contrast, several studies have found that the soy isoflavone genistein stimulates growth of MCF-7 breast cancer cells in culture and as xenoplants in nude mice at low micromolar concentrations similar to those found in the serum of women consuming a soy-based diet (18, 19). Several short-term studies have also reported estrogen-like responses in breast tissue (20) or nipple aspirates (21) of women given soy products. These studies have raised concern that isoflavones may stimulate epithelial cell growth in the breast and uterus and promote development of estrogen-responsive tumors. The purpose of

equine estrogen group, compared with SPIⴙ and SPIⴚ groups, whereas no significant differences were detected between the SPIⴙ and SPIⴚ groups. SPIⴙ treatment resulted in significantly lower serum concentrations of estrone (P < 0.01) and estradiol (P < 0.05) vs. SPIⴚ. Within the SPIⴙ group, serum isoflavone concentrations were inversely correlated with serum estrone and mammary glandular area. These findings suggest that high dietary levels of soy isoflavones do not stimulate breast or uterine proliferation in postmenopausal monkeys and may contribute to an estrogen profile associated with reduced breast cancer risk. (J Clin Endocrinol Metab 89: 3462–3468, 2004)

this study was to evaluate markers of breast and uterine proliferation in response to long-term treatment with soy isoflavones or conjugated equine estrogens (CEE), a common estrogen replacement therapy in women, in a postmenopausal nonhuman primate model. Materials and Methods Animal subjects One hundred eighty-nine adult female premenopausal cynomolgus monkeys (Macaca fascicularis) were obtained from the Institute Pertanian Bogor, Bogor, Indonesia. The reproductive physiology of these animals is similar to that of women in several aspects, including a 28-d menstrual cycle (22) and natural ovarian senescence (23). Human and macaque breasts share similar patterns of lobuloalveolar and ductal development and regression (24), cytokeratin phenotype (25), sex steroid receptor expression (26), steroidogenic enzyme distribution (27), and responses to exogenous estrogens (28, 29). Mammary glands and uteri were obtained from 179 of these animals at necropsy. Average age at the time of necropsy was 12.0 yr as estimated from dental examination at the time of import. All procedures involving animals were conducted in compliance with state and federal laws, standards of the U.S. Department of Health and Human Services, and guidelines established by the Wake Forest University Animal Care and Use Committee.

Study design Abbreviations: BMI, Body mass index; BW, body weight; CEE, conjugated equine estrogen; E1, estrone; E2, estradiol; ER␣, estrogen receptor-␣; E1-S, estrone sulfate; H&E, hematoxylin and eosin; OC, oral contraceptive; PR, progesterone receptor; SPI⫹, diet of soy protein isolate with isoflavones; SPI⫺, diet of soy protein isolate depleted of isoflavones. JCEM is published monthly by The Endocrine Society (http://www. endo-society.org), the foremost professional society serving the endocrine community.

This investigation was part of a large randomized, controlled experiment designed to evaluate multisystem effects of premenopausal oral contraceptives and postmenopausal soy isoflavones and CEE in nonhuman primates. Other aspects of this study have been reported elsewhere (30 –34). The overall study design incorporated premenopausal and postmenopausal treatment phases spanning a total of 5.5 yr, as described previously (30, 31). During the 26-month premenopausal period, half of the animals received, in the diet, a triphasic oral contraceptive (OC) (Triphasil, Wyeth-Ayerst Laboratories, Inc., Philadelphia,

3462

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

PA) containing varying proportions of ethinyl estradiol (0.03– 0.04 mg/ 1800 kcal) and levonorgestrel (0.05– 0.125 mg/1800 kcal) for the initial 21 d of each cycle, with a placebo given for the final 7 d, as in women. All monkeys consumed a diet containing 17% of calories from protein, 45% from fat, 38% from carbohydrates, and 0.28 mg cholesterol/kcal. After the premenopausal phase, all animals were ovariectomized to make them surgically menopausal. The postmenopausal study followed a three-group, parallel arm design and lasted for 36 months. All animals remained in their original social groups. Using a stratified randomization scheme based on premenopausal social group and OC exposure, monkeys were randomly assigned to one of three postmenopausal treatment groups: 1) soy protein isolate depleted of isoflavones (SPI⫺); 2) soy protein isolate with isoflavones (SPI⫹); and 3) SPI⫺ diet with CEE. The SPI⫺ diet contained isolated soy protein that had been alcohol washed to remove the isoflavones. The SPI⫹ treatment group received soy protein isolate containing isoflavones at a dose approximately equivalent to 129 mg/d for women (⬃91 mg genistein, 31 mg daidzein, and 7 mg glycitein). The CEE group received alcohol-washed soy protein isolate (SPI⫺) plus CEE (Premarin, Wyeth-Ayerst Laboratories) at a dose comparable with 0.625 mg/d for women. CEE and isoflavone doses were scaled to 1800 kcal of diet (the estimated daily intake for U.S. women) so that monkeys fed 120 kcal of diet per kilogram of body weight (BW) consumed approximately 8.6 mg isoflavones/kg BW or 0.042 mg CEE/kg BW. This caloric adjustment of dose accounts for differences in metabolic rates between the monkeys and human subjects. The isolated soy proteins used for this study were generously provided by Solae, a division of DuPont (St. Louis, MO). The unextracted soy protein (SUPRO 670-HG) contained, on the average, 1.105 mg genistein, 0.365 mg daidzein, and 0.08 mg glycitein/g soy protein isolate, whereas the alcohol-extracted soy protein (SUPRO 670-IF) contained 0.04 mg genistein, 0.01 mg daidzein, and 0.01 mg glycitein/g isolate (expressed in aglycone units). Soy protein isolate was heat treated before the alcohol extraction to inactivate protease inhibitors. Further details of SPI⫹ and SPI⫺ diets have been described previously (35). Monkeys were fed 120 kcal/kg BW䡠d split into two feedings. Diets were formulated to be isocaloric and equivalent for the macronutrients. Serum isoflavone concentrations (genistein, daidzein, equol, dehydrodaidzein, and o-desmethylangolensin) were measured in serum collected 4 h after provision of the morning diet at month 34 of the postmenopausal period. Isoflavone concentrations were determined by HPLC-mass spectrometry in the laboratory of Dr. Stephen Barnes (University of Alabama, Birmingham, AL), as reported previously (31). The mean total serum isoflavone concentration of the SPI⫹ group was 805 ⫾ 88 nmol/liter aglycone equivalents. Total serum isoflavone concentrations from all SPI⫺ animals were less than 80 nmol/liter.

Necropsy procedures At the end of the postmenopausal phase, monkeys were sedated with ketamine and euthanized using sodium pentobarbital (100 mg/kg, iv) as recommended by the Panel on Euthanasia of the American Veterinary Medical Association. At necropsy, mammary tissues and uteri were removed and fixed immediately at 4 C in fresh 4% paraformaldehyde solution (Fisher Scientific, Raleigh, NC). After 24 h, tissues were transferred to 70% ethanol. Mammary tissues were sectioned sagitally through the nipple and trimmed to 3 cm in length. Uteri were sectioned transversely at the point of greatest diameter. Fixed tissues were embedded in paraffin and sectioned to 5 ␮m in thickness for hematoxylin and eosin (H&E) and immunohistochemical staining.

Histomorphometry Breast and uterine epithelial area and thickness were quantified by histomorphometry, as described previously (28). Briefly, H&E-stained slides were digitized using a Hitachi VK-C370 camera and video capture board (Scion LG-3; Scion, Inc., Frederick, MD), and measurements were taken with public domain software (NIH Image version 1.60; available at http://rsb.info.nih.gov/nih-image/). Three microscopic fields were randomly selected and examined at a magnification of ⫻20; epithelial area was determined by manual tracing of lobuloalveolar (breast) or glandular (endometrium) units and expressed as a percentage of the total area examined. Mammary pad and endometrial thickness were measured at the point of greatest perpendicular depth. H&E-stained

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468 3463

mammary glands and uteri were also evaluated qualitatively for histologic changes by two board-certified veterinary pathologists (J.M.C., N.D.K.). All measurements were made blinded to treatment group. Adjacent tissue sections from each animal were used for histomorphometry and immunostaining.

Immunohistochemistry Immunostaining procedures were performed on fixed, paraffinembedded tissues using commercially available primary monoclonal antibodies for Ki67 (Ki67-MM1, Dako, Carpinteria, CA), progesterone receptor (PR) (NCL-PGR, Novocastra, Newcastle-upon-Tyne, UK), and estrogen receptor-␣ (ER␣) (NCL-ER-6F11, Novocastra). Ki67 and PR were used as markers of proliferation and estrogenic stimulation, respectively. Staining methods included antigen retrieval with citrate buffer (pH 6.0), biotinylated rabbit antimouse Fc antibody as a linking reagent, alkaline phosphatase-conjugated streptavidin as the label, and Vector Red as the chromogen. Immunostaining components were obtained as a kit (Vector Laboratories, Burlingame, CA). Staining for Ki67, PR, and ER␣ was quantified by a computer-assisted counting technique, using a grid filter to select cells for counting (36) and our modified procedure of cell selection, described previously (26). Numbers of positively stained cells were expressed as a percentage of the total number examined (100 cells).

Hormone assays Hormone concentrations were measured from serum collected at a preselected time point in month 29 of the postmenopausal period. Estrogen assays were run on a subset of animals based on serum availability at this time point. Blood samples were collected via femoral puncture after the animals entered a squeeze cage and were sedated with ketamine HCl (10 mg/ml, im), 4 h after the morning meal within 1 h of each other. Blood collections were staggered so that all animals in a single pen were sampled on the same day, and all animals were sampled at the same time from the start of treatment. Serum was frozen at ⫺80 C immediately after collection for later analysis. Concentrations of estradiol (E2), estrone (E1), and estrone sulfate (E1-S) were quantitated by RIA using commercially available kits and protocols from Diagnostic Systems Laboratories (E2, DSL-4800 ultrasensitive; E1, DSL-8700; E1-S, DSL-5400; Webster, TX). For E2 assays, serum (0.5 ml) was extracted by adding ethyl ether (4 ml) and vortexing for 5 min. The aqueous layer was frozen in a dry ice/isopropanol bath, and the organic phase was decanted. Extracts were dried and reconstituted with zero standard serum from the RIA kit. For E2 values below the lowest standard in the kit (5.0 pg/ml), a predetermined surrogate value of 4.0 pg/ml was used for statistical analysis. Assays were performed at either the Yerkes Regional Primate Research Center Endocrinology Laboratory (E1) or the Clinical Pathology Laboratory at the Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine (E2, E1-S). Ranges for calibration standards are as follows: E2 (5–750 pg/dl), E1 (7.5–2000 pg/ml), and E1-S (0.05–90 ng/ml). Intraassay coefficients of variation are as follows: E2, 2.70%; E1, less than 10%; and E1-S, 9.76%.

Statistics All data were subjected to two-way ANOVA using premenopausal treatment (OC, no OC) and postmenopausal treatment (SPI⫺, SPI⫹, CEE) as between-subject factors. Body weight was significantly correlated with serum E1 and E1-S and was thus used as a covariate for all measures. All variables were evaluated for their distribution and equality of variances between groups, and log10 transformations were performed for all variables to improve normality and homogeneity of variance. Data in all figures represent retransformed values. A two-tailed significance level of 0.05 was chosen for all comparisons. Analyses were done using the SAS statistical package (version 6.08; SAS Institute, Cary, NC).

Results Age, body weight, and body mass index (BMI)

No significant differences were observed among postmenopausal groups in age, BW, and BMI (BW/trunk length2)

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

3464

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468

during the postmenopausal period (Table 1). Mean change in body weight during postmenopausal treatment was ⫹0.51 ⫾ 0.08, ⫹0.54 ⫾ 0.08, and ⫹0.46 ⫾ 0.07 kg for SPI⫺, SPI⫹, and CEE groups, respectively (by ANOVA, P ⫽ 0.74). Mean change in postmenopausal BMI was ⫹5.30 ⫾ 0.94, ⫹5.13 ⫾ 0.94, and ⫹3.85 ⫾ 0.91 kg/m2 for SPI⫺, SPI⫹, and CEE groups, respectively (by ANOVA, P ⫽ 0.48). Mammary gland and uterine measures

Three years of SPI⫹ treatment did not significantly alter epithelial area, Ki67 expression, or sex steroid receptor expression in the breast or uterus, compared with the SPI⫺ group (Figs. 1–3). The only measure that was significantly different between SPI⫹ and SPI⫺ groups was mammary thickness, which was lower in the SPI⫹ animals (P ⬍ 0.05). In contrast, CEE treatment resulted in significantly greater mammary gland and endometrial epithelial area, Ki67, and PR, compared with both SPI⫺ and SPI⫹ groups (Figs. 1–3). ER␣ expression in the CEE group was significantly higher in the mammary gland but not endometrium relative to SPI⫺ and SPI⫹ groups (Figs. 1 and 2). On histology, mild to moderate lobular enlargement was seen in the mammary gland of two of 57 SPI⫺, none of 60 SPI⫹, and 31 of 63 CEE-treated animals. Small focal papillary ductal hyperplasias were seen in three of 57 SPI⫺, none of 60 SPI⫹, and one of 63 CEEtreated animals. Endometrial hyperplasia of moderate to marked degree was present in none of 57 SPI⫺, none of 60 SPI⫹, and 26 of 62 CEE-treated animals. Minimal or mild proliferative changes were seen in three of 57 SPI⫺, 1 of 60 SPI⫹, and 32 of 60 CEE-treated animals. All animals in this study had histologic evidence of previous pregnancy as indicated by adventitial expansion and accumulation of extracellular matrix around the myometrial veins (37). Substantial interindividual variation was observed in total plasma isoflavone concentrations within the SPI⫹ group (31). Stratification of SPI⫹ animals into tertiles based on total plasma isoflavones revealed an inverse association with mammary epithelial area (p for trend ⫽ 0.02) (Fig. 4); Ki67 and PR expression levels were also lower in the high-isoflavone tertile, although tertile differences were not statistically significant (data not shown). Prior treatment with OCs had no significant carryover effects on mammary gland proliferation at the end of the postmenopausal period; however, postmenopausal uterine weight, endometrial thickness, and endometrial epithelial area were significantly lower in animals previously treated with OCs (Table 2).

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

Serum estrogens

SPI⫹ treatment resulted in significantly lower serum E1 (⫺24%) and E2 (⫺20%) concentrations vs. the SPI⫺ group (Table 3). E1-S (⫺14%) was lower in the SPI⫹ group but not significantly different from SPI⫺. E2 concentrations were below the lowest standard (⬍5.0 pg/ml) in 76% of SPI⫹, 43% of SPI⫺, and no CEE animals. Total plasma isoflavone levels for SPI⫹ animals correlated inversely with serum E1 concentrations (r ⫽ ⫺0.38, P ⬍ 0.005), with markedly lower E1 in the high-isoflavone tertile when compared with the other tertiles (P ⬍ 0.01) (Fig. 4). Among isoflavone metabolites, the negative correlation with E1 was strongest for equol (r ⫽ ⫺0.42; P ⬍ 0.001). Body weight was a significant covariate for E1 (P ⫽ 0.002) and E1-S (P ⫽ 0.04) but not E2 (P ⫽ 0.11). Postmenopausal serum estrogen concentrations were not affected by prior treatment with OCs (P ⬎ 0.05 for E1, E2, and E1-S). Discussion

This is the first long-term randomized, controlled trial designed to evaluate soy isoflavone effects on breast and endometrial proliferation. In this 3-yr study, high dietary levels of soy isoflavones did not stimulate proliferation or estrogen-responsive markers in the normal postmenopausal breast and uterus of monkeys. Strengths of this study included the use of a primate model, the extended duration of treatment, relatively large sample size, and prospective parallel-arm design. Limitations include the use of hormonally unstimulated surgically postmenopausal monkeys that have lower endogenous estrogen concentrations, compared with naturally menopausal women (presumably due to less adipose tissue and the lack of ovary-derived C19 estrogen precursors). This relative hypoestrogenemia in our model may have obscured potential antiestrogen effects of soy isoflavones (38) by lowering baseline proliferation. Second, the predominant isoflavone metabolite present in the serum of all isoflavone-treated animals was equol, which comprised over half of the total serum isoflavones (31). Equol is an isoflavone metabolite produced endogenously in only about one third of people consuming soy (39). Whereas the direct effects of equol have not been clearly identified, equol-producing women have previously been reported to have lower circulating estrogens than equol nonproducers (40), consistent with our data. Results of this study suggest that the soy isoflavones may reduce concentrations of E1 and E2, which are important determinants of breast cancer risk in postmenopausal

TABLE 1. Age, body weight, and BMI of postmenopausal groups

Age (yr) Body weight initial (kg) Body weight final (kg) BMI initial (kg/m2) BMI final (kg/m2)

SPI⫺ (n ⫽ 57)

SPI⫹ (n ⫽ 60)

CEE (n ⫽ 62)

P (ANOVA)

12.24 ⫾ 0.15 2.84 ⫾ 0.05 3.34 ⫾ 0.10 39.1 ⫾ 0.58 44.3 ⫾ 1.11

12.08 ⫾ 0.14 2.83 ⫾ 0.05 3.37 ⫾ 0.10 39.1 ⫾ 0.57 44.2 ⫾ 1.11

11.83 ⫾ 0.14 2.83 ⫾ 0.05 3.29 ⫾ 0.10 38.6 ⫾ 0.57 42.6 ⫾ 1.08

0.13 0.99 0.85 0.76 0.47

Values represent means ⫾ SE. Initial, Start of postmenopausal treatment; final, end of postmenopausal treatment; SPI⫺, soy protein without isoflavones; SPI⫹, soy protein with 129 mg/d equivalent of isoflavones; CEE, SPI⫺ with CEE at a dose scaled to approximate 0.625 mg/d in women.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468 3465

FIG. 1. Mammary gland immunohistochemical measurements of surgically postmenopausal monkeys given SPI⫺ (n ⫽ 55), SPI⫹ (n ⫽ 55), or SPI⫺ diet with CEE (n ⫽ 60) for 36 months. Data represent retransformed means ⫾ SE. Ki67, MM1 proliferation marker; ER, ER-␣. *, Significant difference from SPI⫺ group (P ⬍ 0.01) and SPI⫹ group (P ⬍ 0.05). **, Significant difference from SPI⫺ and SPI⫹ groups (P ⬍ 0.01).

FIG. 2. Endometrial immunohistochemical measurements of surgically postmenopausal monkeys given SPI⫺ (n ⫽ 55), SPI⫹ (n ⫽ 56), or SPI⫺ diet with CEE (n ⫽ 61) for 36 months. Data represent retransformed means ⫾ SE. Ki67, MM1 proliferation marker; ER, ER-␣. **, Significant difference from SPI⫺ and SPI⫹ groups (P ⬍ 0.01).

women (41). This finding is supported by epidemiologic (42) and short-term intervention (43) studies in postmenopausal women as well as in vitro studies showing that genistein may modulate key enzymes involved in estrogen biosynthesis

(44 – 47). In particular, isoflavones may inhibit 17␤-hydroxysteroid dehydrogenase type I (44 – 45) and aromatase (47), which regulate peripheral synthesis of E2. However, we cannot exclude potential estrogen-lowering effects of other li-

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

3466

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468

FIG. 3. Mammary gland and endometrial histomorphometric measurements of surgically postmenopausal monkeys given SPI⫺ (n ⫽ 55), SPI⫹ (n ⫽ 55), or SPI⫺ diet with CEE (n ⫽ 60) for 36 months. Data represent retransformed means ⫾ SE. *, Significant difference from SPI⫺ and CEE groups (P ⬍ 0.05). **, Significant difference from SPI⫺ and SPI⫹ groups (P ⬍ 0.01).

pophilic compounds in soy protein such as sterols and saponins that may have been removed during isoflavone extraction. In the present study, postmenopausal treatment with CEE increased mammary gland proliferation, ER␣ expression, and PR expression. This finding is similar to that of several smaller studies in monkeys (28, 29) as well as observational studies of women (48, 49). Whether a modest increase in breast proliferation as seen in this study translates into higher breast cancer risk in postmenopausal women is unclear. Evidence from several large observational studies in women indicates that current users of estrogen-only therapy have a marginally significant increase in relative risk (from 1.06 to 1.32) vs. nonusers (50 –52), although consensus regarding CEE effects on breast cancer risk is still lacking. Breast cancer risk associated with hormone replacement therapy is higher in lean women with lower endogenous estrogens, compared with those with a higher BMI (53). Given the relative hypoestrogenism of our model, the effects of CEE seen in this study may be greater than those seen in more estrogenreplete postmenopausal women. It should also be noted that in our model CEE with a progestin induced greater breast

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

FIG. 4. Mammary gland epithelial area and serum estrone measurements for the animals fed SPI⫹ divided into tertiles based on plasma isoflavone concentrations (n ⫽ 18 –19/group). Data represent retransformed means ⫾ SE. *, Significant difference from low-isoflavone tertile (P ⬍ 0.05).

proliferation than CEE alone (28, 29), consistent with human data showing increased breast cancer risk with combined therapy (51, 52). The marked hyperplastic effect of CEE in the endometrium is consistent with previous monkey data (54) as well as human studies showing increased endometrial proliferation (55) and cancer risk (56) in women taking unopposed CEE. In this study we observed no significant carryover effects of premenopausal OC treatment on breast proliferation, in support of studies in women showing no long-term effects of prior OC use on breast cancer risk (57). In contrast, several markers of uterine proliferation were significantly lower in OC-treated animals 3 yr into the postmenopausal period. Interestingly, this finding is consistent with studies of women showing a persistent protective effect of combination OCs against endometrial cancer (58). The role of soy isoflavones in cancer risk has received considerable debate in recent years, and safety concerns remain that soy isoflavones may promote breast and endometrial cell growth through estrogen-like actions. Findings of this study indicate that high dietary levels of soy isoflavones

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468 3467

TABLE 2. Carryover effects of prior oral contraceptive treatment on postmenopausal mammary gland and uterine proliferation

Mammary gland thickness (mm) Mammary gland epithelial area (% total) Ki67 lobules (% ⫹ cells) Ki67 ducts (% ⫹ cells) Endometrium thickness (mm) Endometrium epithelial area (% total) Uterine weight (gm) Ki67 superficial glands (% ⫹ cells) Ki67 basal glands (% ⫹ cells)

OC⫺ (n ⫽ 84)

OC⫹ (n ⫽ 86)

P (ANCOVA)

1.97 (⫹0.06, ⫺0.06) 0.80 (⫹0.09, ⫺0.08) 6.79 (⫹0.85, ⫺0.76) 0.66 (⫹0.14, ⫺0.11) 1.42 (⫹0.08, ⫺0.08) 11.28 (⫹0.44, ⫺0.42) 2.70 (⫹0.17, ⫺0.16) 6.10 (⫹0.98, ⫺0.85) 1.62 (⫹0.18, ⫺0.16)

1.97 (⫹0.06, ⫺0.06) 0.92 (⫹0.10, ⫺0.09) 5.31 (⫹0.67, ⫺0.60) 0.64 (⫹0.13, ⫺0.11) 1.14 (⫹0.06, ⫺0.06) 9.94 (⫹0.38, ⫺0.37) 2.22 (⫹0.14, ⫺0.13) 4.54 (⫹0.75, ⫺0.64) 1.54 (⫹0.18, ⫺0.16)

0.98 0.36 0.15 0.91 0.005 0.02 0.03 0.17 0.73

Values represent retransformed means ⫾ SE. ANCOVA adjusted for body weight and postmenopausal treatment. OC⫺, No premenopausal OC treatment; OC⫹, premenopausal OC treatment. TABLE 3. Effects of postmenopausal treatment with soy isoflavones or conjugated estrogens on serum estrogens

Estrone (pg/ml) Estradiol (pg/ml) Estrone-sulfate (ng/ml)

SPI⫺

SPI⫹

CEE

50.0 (⫹3.1, ⫺2.9) n ⫽ 57 5.91 (⫹0.39, ⫺0.36) n ⫽ 46 0.36 (⫹0.04, ⫺0.03) n ⫽ 42

37.8 (⫹2.5, ⫺2.3) n ⫽ 54 4.71 (⫹0.31, ⫺0.29) n ⫽ 47 0.31 (⫹0.03, ⫺0.03) n ⫽ 46

351.3 (⫹21.1, ⫺19.9) n ⫽ 51 22.48 (⫹1.27, ⫺1.20) n ⫽ 62 11.13 (⫹0.96, ⫺0.88) n ⫽ 49

P ANCOVA

SPI⫺ vs. SPI⫹

SPI⫺ vs. CEE

SPI⫹ vs. CEE

⬍0.0001

0.002

⬍0.0001

⬍0.0001

⬍0.0001

0.01

⬍0.0001

⬍0.0001

⬍0.0001

0.26

⬍0.0001

⬍0.0001

Values represent retransformed means ⫾ SE. ANCOVA adjusted for body weight and prior OC treatment. SPI⫺, Soy protein without isoflavones; SPI⫹, soy protein with 129 mg/d equivalent of isoflavones; CEE, SPI⫺ with CEE at a dose scaled to approximate 0.625 mg/d in women. For conversion to SI units, multiply by the following conversion factors: 3.70 for estrone (picomoles per liter), 3.67 for estradiol (picomoles per liter), and 2.85 for estrone-sulfate (nanomoles per liter).

do not stimulate proliferation or induce markers of estrogenicity in the normal postmenopausal breast and uterus of monkeys. Furthermore, higher isoflavone concentrations may contribute to an estrogen profile associated with reduced cancer risk. These findings should be of interest to the many women at high risk of breast cancer who are currently taking supplemental soy products. Acknowledgments The authors thank Jean Gardin, Brian McCollough, Kelly Thompson, Dianna Swaim, Tim Vest, and Matt Dwyer for their technical contributions; Professor Thomas B. Clarkson for guidance and assistance; and Professor Stephen Barnes for isoflavone measurements. For hormone measurements, we thank the staff of the Endocrine Core Lab (Yerkes Primate Research Center) and the Clinical Chemistry and Endocrinology Lab (Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine). Soy products were generously provided by Solae (a division of DuPont, St. Louis, MO). Received December 2, 2003. Accepted April 6, 2004. Address all correspondence and requests for reprints to: Charles E. Wood, D.V.M., Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1040. E-mail: chwood@wfubmc. edu. This work was supported by Program Project Grant HL-45666 from the National Institutes of Health/National Heart, Lung, and Blood Institute, Bethesda, Maryland, NIH/National Center for Complementary and Alternative Medicine R01-AT00639, and NIH/National Center for Research Resources T32 RR 07009.

References 1. Newton KM, Buist DSM, Keenan NL, Anderson LA, LaCroix AZ 2002 Use of alternative therapies for menopause symptoms: results of a populationbased survey. Obstet Gynecol 100:18 –25

2. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA 2002 Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 23:501–509 3. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC 2002 Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 23:1491–1496 4. Dai Q, Shu XO, Jin F, Potter JD, Kushi LH, Teas J, Gao YT, Zheng W 2001 Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 85:372–378 5. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S 2003 Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906 –913 6. Ingram D, Sanders K, Kolybaba M, Lopez D 1997 Case-control study of phyto-oestrogens and breast cancer. Lancet 350:990 –994 7. Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, Franke AA 1999 Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 8:35– 40 8. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN 1997 Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146:294 –306 9. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM 2003 Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 95:1158 –1164 10. Constantinou AI, Mehta RG, Vaughan A 1996 Inhibition of N-methyl-Nnitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Res 16:3293–3298 11. Lamartiniere CA, Moore J, Holland M, Barnes S 1995 Neonatal genistein chemoprevents mammary cancer. Proc Soc Exp Biol Med 208:120 –123 12. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592–5595 13. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB, Larsen AK 1989 Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49:5111–5117 14. Barnes S, Peterson TG 1995 Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 208:103–108 15. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I 1994 Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30:1675–1682 16. Shao ZM, Wu J, Shen ZZ, Barsky SH 1998 Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851– 4857 17. Constantinou AI, Kamath N, Murley JS 1998 Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur J Cancer 34:1927–1934

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.

3468

J Clin Endocrinol Metab, July 2004, 89(7):3462–3468

18. Hsieh CY, Santell RC, Haslam SZ, Helferich WG 1998 Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58:3833–3839 19. Wang TT, Sathyamoorthy N, Phang JM 1996 Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17:271–275 20. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ 1999 Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 84:4017– 4024 21. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L 1996 Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 5:785–794 22. Corner GW 1923 Ovulation and menstruation in Macacus rhesus. Contrib Embryol 15:73–102 23. Gilardi KV, Shideler SE, Valverde CR, Roberts JA, Lasley BL 1997 Characterization of the onset of menopause in the rhesus macaque. Biol Reprod 57:335–340 24. Speert H 1948 The normal and experimental development of the mammary gland of the rhesus monkey with some pathologic correlations. Contrib Embryol 32:9 – 65 25. Tsubura A, Hatano T, Hayama S, Morii S 1991 Immunophenotypic difference of keratin expression in normal mammary glandular cells from five different species. Acta Anatomica 140:287–293 26. Cline JM, Soderqvist G, von Schoultz B, Skoog L 1997 Regional distribution of proliferating cells and hormone receptors in the mammary gland of surgically postmenopausal macaques. Gynecol Obstet Invest 44:41– 46 27. Labrie F, Belanger A, Simard J, Van L, Labrie C 1995 DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 774:16 –28 28. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B 1998 Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 48:221–229 29. Cline JM, Register TC, Clarkson TB 2002 Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 9:422– 429 30. Kaplan JR, Manuck SB, Anthony MS, Clarkson TB 2002 Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol 99:381–388 31. Clarkson TB, Anthony MS, Morgan TM 2001 Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 86:41– 47 32. Shively CA 1998 Behavioral and neurobiological effects of estrogen replacement therapy and a history of triphasic oral contraceptive exposure. Psychoneuroendocrinology 23:713–732 33. Register TC, Jayo MJ, Anthony MS 2003 Soy phytoestrogens do not protect against bone loss in postmenopausal monkeys. J Clin Endocrinol Metab 88: 4362– 4370 34. Shively CA, Mirkes SJ, Lu NZ, Henderson JA, Bethea CL 2003 Soy and social stress affect serotonin neurotransmission in primates. Pharmacogenomics J 3:114 –121 35. Anthony MS, Clarkson TB, Bullock BC, Wagner JD 1997 Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol 17: 2524 –2531 36. Lindholm J, van Diest PJ, Haffner D, Mikuz G, Weger AR 1992 A morphometric filter improves the diagnostic value of morphometric analyses of frozen histopathologic sections from mammary tumors. Anal Cell Pathol 4:443– 449 37. Cline JM, Bain F 1995 Uterine vascular changes indicating prior pregnancy in macaques. Vet Pathol 32:585 38. Foth D, Cline JM 1998 Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 68:1413S–1417S 39. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M 1984 Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 40:569 –578

Wood et al. • Breast and Uterine Effects of Soy Isoflavones

40. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS 2000 Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:581–586 41. Endogenous Hormones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606 – 616 42. Wu AH, Stanczyk FZ, Seow A, Lee HP, Yu MC 2002 Soy intake and other lifestyle determinants of serum estrogen levels among postmenopausal Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 11:844 – 851 43. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS 1999 Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 84:3479 –3484 44. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G 1998 Aromatase and 17␤-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett 133: 101–106 45. Makela S, Poutanen M, Lehtimaki J, Kostian ML, Santti R, Vihko R 1995 Estrogen-specific 17␤-hydroxysteroid oxidoreductase type 1 (E. C. 1.1.1.62) as a possible target for the action of phytoestrogens. Exp Biol Med 208:51–59 46. Brueggemeier RW, Gu X, Mobley JA, Joomprabutra S, Bhat AS, Whetstone JL 2001 Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann NY Acad Sci 948: 51– 66 47. Fritz WA, Cotroneo MS, Wang J, Eltoum IE, Lamartiniere CA 2003 Dietary diethylstilbestrol but not genistein adversely affects rat testicular development. J Nutr 133:2287–2293 48. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ 1999 Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559 – 4565 49. Khan SA, Rogers MAM, Khurana KK, Meguid MM, Numann PJ 1998 Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37– 42 50. Ross RK, Paganini-Hill A, Wan PC, Pike MC 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328 –332 51. Schairer C, Lubin J, Troisi R Sturgeon S, Brinton L, Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485– 491 52. Beral V, Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419 – 427 53. Collaborative Group on Hormonal Factors in Breast Cancer 1997 Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059 54. Cline JM, Register TC, Clarkson TB 2002 Comparative effects of tibolone and conjugated equine estrogens with and without medroxyprogesterone acetate on the reproductive tract of female cynomolgus monkeys. Menopause 9:242– 252 55. The Writing Group for the PEPI Trial 1996 Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 275:370 –375 56. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D 1995 Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304 –313 57. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK 2002 Oral contraceptives and the risk of breast cancer. N Engl J Med 346:2025–2032 58. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development 1983 Oral contraceptive use and the risk of endometrial cancer. JAMA 249: 1600 –1604

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 17 January 2017. at 13:51 For personal use only. No other uses without permission. . All rights reserved.